Eric T. Gangl

2.1k total citations
33 papers, 733 citations indexed

About

Eric T. Gangl is a scholar working on Molecular Biology, Oncology and Pharmacology. According to data from OpenAlex, Eric T. Gangl has authored 33 papers receiving a total of 733 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 7 papers in Oncology and 5 papers in Pharmacology. Recurrent topics in Eric T. Gangl's work include Cancer therapeutics and mechanisms (5 papers), Analytical Chemistry and Chromatography (4 papers) and Estrogen and related hormone effects (4 papers). Eric T. Gangl is often cited by papers focused on Cancer therapeutics and mechanisms (5 papers), Analytical Chemistry and Chromatography (4 papers) and Estrogen and related hormone effects (4 papers). Eric T. Gangl collaborates with scholars based in United States, United Kingdom and Singapore. Eric T. Gangl's co-authors include Paul Vouros, Nicolas Gerber, Ilya Utkin, Neil Spooner, Robert J. Turesky, Barry L. Karger, František Foret, Haihong Zhou, James S. Scott and Petar Pop-Damkov and has published in prestigious journals such as Journal of Clinical Oncology, Analytical Chemistry and Cancer Research.

In The Last Decade

Eric T. Gangl

30 papers receiving 705 citations

Peers

Countries citing papers authored by Eric T. Gangl

Since Specialization

Citations

This map shows the geographic impact of Eric T. Gangl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric T. Gangl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric T. Gangl more than expected).

Fields of papers citing papers by Eric T. Gangl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric T. Gangl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric T. Gangl. The network helps show where Eric T. Gangl may publish in the future.

Co-authorship network of co-authors of Eric T. Gangl

This figure shows the co-authorship network connecting the top 25 collaborators of Eric T. Gangl. A scholar is included among the top collaborators of Eric T. Gangl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric T. Gangl. Eric T. Gangl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Open‐Label Study Assessing Relative and Absolute Bioavailability of Oral Camizestrant Formulations and Food Effects in Healthy Postmenopausal Women 2026 ·Clinical and Translational Science ·(unknown), Helena Engman, Nigel A. S. Taylor, (unknown), Rhiannon Maudsley, (unknown), Alastair Mathewson, Ryan A. Bragg, (unknown), Eric T. Gangl, Teresa Klinowska, (unknown), (unknown), (unknown), John McDermott, (unknown)	0
2	The DNA-PK inhibitor AZD7648 alone or combined with pegylated liposomal doxorubicin in patients with advanced cancer: results of a first-in-human Phase I/IIa study 2025 ·British Journal of Cancer ·Timothy A. Yap, Patricia LoRusso, Rowan Miller, Rebecca Kristeleit, Amanda G. Paulovich, Stephen McMorn, Lenka Oplustil O’Connor, (unknown), Paola Marco‐Casanova, Eric T. Gangl, Bharat Patel, Mark J. O’Connor, Emma Dean, (unknown), Ruth Plummer	2
3	The application of mechanistic absorption, distribution, metabolism and excretion studies and physiologically-based pharmacokinetic modeling in the discovery of the next-generation oral selective estrogen receptor degrader camizestrant to achieve an acceptable human pharmacokinetic profile 2025 ·Drug Metabolism and Disposition ·Eric T. Gangl, (unknown), (unknown), (unknown), Petar Pop-Damkov, Ujjal Sarkar, Linda C. Andersson, (unknown), James S. Scott, Adrian J. Fretland, Teresa Klinowska, Dermot F. McGinnity	2
4	Design and Synthesis of Acyclic Boronic Acid Arginase Inhibitors 2024 ·Journal of Medicinal Chemistry ·(unknown), Brian Aquila, (unknown), M. Raymond V. Finlay, Eric T. Gangl, (unknown), Scott N. Mlynarski, Jens Petersen, Petar Pop-Damkov, Sha Li, Iain Simpson, (unknown), Sharon Tentarelli, Haixia Wang, Qing Ye, Xiaolan Zheng	2
5	A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer 2024 ·Cancer Immunology Immunotherapy ·Gerald S. Falchook, James A. Reeves, Sunil Gandhi, David R. Spigel, Edward Arrowsmith, Daniel J. George, Janet L. Karlix, Gayle P. Pouliot, Maureen M. Hattersley, Eric T. Gangl, (unknown), (unknown), Deanna L. Russell, (unknown), Rakesh Kumar, Emerson A. Lim	8
6	A phase II study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients with progressive, metastatic, castration-resistant prostate cancer 2024 ·ESMO Open ·Teresa Alonso‐Gordoa, Michael Goodman, Christof Vulsteke, Guilhem Roubaud, (unknown), Mamta Parikh, Josep M. Piulats, (unknown), Gary D. James, Riccardo Cavazzina, Eric T. Gangl, (unknown), Gayle P. Pouliot, Rakesh Kumar, Christopher J. Sweeney	5
7	1396P Phase II study of AZD4635 in combination with durvalumab or oleclumab in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) 2022 ·Annals of Oncology ·Emerson A. Lim, James A. Reeves, (unknown), David R. Spigel, Edward Arrowsmith, D. George, Janet L. Karlix, Gayle P. Pouliot, Maureen M. Hattersley, Eric T. Gangl, Glen James, (unknown), Deanna L. Russell, (unknown), Rakesh Kumar, Gerald S. Falchook	3
8	Generation of High-Quality Pharmacokinetic Data From Parallel Tail Vein Dosing And Bleeding in Non-cannulated Rats 2021 ·Journal of Pharmaceutical Sciences ·David J. Wagner, (unknown), (unknown), (unknown), (unknown), Eric T. Gangl	1
9	Quantitative Evaluation of Dendritic Nanoparticles in Mice: Biodistribution Dynamics and Downstream Tumor Efficacy Outcomes 2021 ·Molecular Pharmaceutics ·(unknown), Douglas Ferguson, Weimin Li, Victorine Muse, Francis D. Gibbons, Silvia Sonzini, (unknown), Petar Pop-Damkov, Eric T. Gangl, (unknown), Shenghua Wen, Alwin G. Schuller, Sanyogitta Puri, Mariarosa Mazza, Marianne Ashford, Adrian J. Fretland, Dermot F. McGinnity, Rhys D.O. Jones	1
10	Abstract 4523: Inhibition of arginase in combination with anti-PDL1 leads to increased infiltration and activation of CD8+ T cells, NK cells, and CD103+ dendritic cells in mouse syngeneic tumor models 2020 ·Cancer Research ·Alwin G. Schuller, (unknown), (unknown), (unknown), Yanjun Wang, (unknown), Sharon Tentarelli, Eric T. Gangl, (unknown), Kristina M. Ilieva, Theresa A. Proia, Scott N. Mlynarski, (unknown), Wenlin Shao	4
11	Development of a quantification method for adenosine in tumors by LC-MS/MS with dansyl chloride derivatization 2018 ·Analytical Biochemistry ·Kelly Goodwin, Eric T. Gangl, Ujjal Sarkar, Petar Pop-Damkov, Natalie H. Jones, Alexandra Borodovsky, Richard Woessner, Adrian J. Fretland	19
12	Mouse Red Blood Cell–Mediated Rare Xenobiotic Phosphorylation of a Drug Molecule Not Intended to Be a Kinase Substrate 2017 ·Drug Metabolism and Disposition ·Chungang Gu, Shenghua Wen, P. Doig, Eric T. Gangl, Xiaolan Zheng, Yanjun Wang, Jeffrey W. Johannes	1
13	Selective Time- and NADPH-Dependent Inhibition of Human CYP2E1 by Clomethiazole 2016 ·Drug Metabolism and Disposition ·David M. Stresser, Elke S. Perloff, (unknown), (unknown), Shangara S. Dehal, (unknown), (unknown), Eric T. Gangl	19
14	Assessment of cisplatin-induced kidney injury using an integrated rodent platform 2013 ·Toxicology and Applied Pharmacology ·Yafei Chen, David Brott, Wei Luo, Eric T. Gangl, Harriet Kamendi, Herbert Barthlow, (unknown), James Fikes, Lewis B. Kinter, Jean‐Pierre Valentin, Russell Bialecki	28
15	Antibiotic Optimization and Chemical Structure Stabilization of Thiomuracin A 2012 ·Journal of Medicinal Chemistry ·Matthew J. LaMarche, Jennifer A. Leeds, (unknown), Eric T. Gangl, Philipp Krastel, Georg Neckermann, (unknown), Michael A. Patane, (unknown), (unknown), Donghui Yu	30
16	A new structural alert for benzimidazoles: 2,6-Dimethylphenyl substituents increase mutagenic potential and time-dependent CYP3A4 inhibition risk 2011 ·Bioorganic & Medicinal Chemistry Letters ·Young‐Shin Kwak, Gary M. Coppola, Cornelia J. Forster, (unknown), (unknown), (unknown), Alan D. Neubert, (unknown), (unknown), Susanne Glowienke, (unknown), (unknown), (unknown), Eric T. Gangl, Mithat Gunduz, Monish Jain, Jenny Zhan, Michael H. Serrano‐Wu	0
17	Structural elucidation of metabolites of ritonavir and indinavir by liquid chromatography–mass spectrometry 2002 ·Journal of Chromatography A ·Eric T. Gangl, Ilya Utkin, Nicolas Gerber, Paul Vouros	71
18	Subatmospheric electrospray interface for coupling of microcolumn separations with mass spectrometry 2000 ·Electrophoresis ·František Foret, Haihong Zhou, Eric T. Gangl, Barry L. Karger	57
19	Determination of in Vitro- and in Vivo-Formed DNA Adducts of 2-Amino-3-methylimidazo[4,5-f]quinoline by Capillary Liquid Chromatography/Microelectrospray Mass Spectrometry 1999 ·Chemical Research in Toxicology ·Eric T. Gangl, Robert J. Turesky, Paul Vouros	43
20	Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. 1998 ·PubMed ·(unknown), (unknown), Ilya Utkin, Eric T. Gangl, Paul Vouros, (unknown), (unknown), (unknown), Nicolas Gerber	194

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact